NeoGenomics (NASDAQ:NEO) Price Target Raised to $15.00 at Needham & Company LLC

NeoGenomics (NASDAQ:NEO) had its price objective boosted by equities researchers at Needham & Company LLC from $14.00 to $15.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target would suggest a potential upside of 31.12% from the stock’s previous close.

NEO has been the subject of several other reports. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a research note on Tuesday, October 28th. Finally, TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, NeoGenomics has an average rating of “Hold” and an average target price of $12.13.

NeoGenomics Stock Up 0.5%

NEO stock opened at $11.44 on Tuesday. The company’s 50 day simple moving average is $12.17 and its 200-day simple moving average is $10.11. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.62. The firm has a market capitalization of $1.48 billion, a P/E ratio of -13.00 and a beta of 1.58.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $190.17 million for the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The company’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.04 EPS. As a group, equities research analysts anticipate that NeoGenomics will post -0.2 EPS for the current year.

Insider Buying and Selling at NeoGenomics

In other news, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares of the company’s stock, valued at approximately $372,996. This represents a 40.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors have recently modified their holdings of NEO. Royal Bank of Canada boosted its position in shares of NeoGenomics by 51.2% in the first quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock valued at $532,000 after acquiring an additional 18,966 shares during the period. AQR Capital Management LLC acquired a new stake in NeoGenomics in the 1st quarter worth $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of NeoGenomics by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock worth $719,000 after purchasing an additional 3,254 shares during the period. Intech Investment Management LLC raised its position in shares of NeoGenomics by 19.7% during the first quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock valued at $1,441,000 after buying an additional 24,965 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of NeoGenomics by 118.9% in the second quarter. CWM LLC now owns 13,787 shares of the medical research company’s stock valued at $101,000 after buying an additional 7,488 shares during the period. Institutional investors own 98.50% of the company’s stock.

Trending Headlines about NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q4 results beat estimates: NeoGenomics reported $0.06 EPS vs. $0.04 expected and $190.17M revenue (vs. ~$188.3M est.), with revenue up ~10.6% YoY — proof of revenue momentum. Zacks Q4 Beat
• Positive Sentiment: Product tailwinds: Management emphasized traction in RaDaR ST and the PanTracer family (PanTracer Pro launch), which are positioned to accelerate genomic testing sales and could drive mid‑term revenue upside. SA: Revenue Target & Initiatives
• Neutral Sentiment: FY‑2026 revenue guide set to $793M–$801M (around consensus ~$796M) — guidance is basically in-line, not a clear upside surprise; the company’s EPS guidance was not a standout compared with expectations. SA: Guidance
• Neutral Sentiment: Investors can review the full earnings call and slide deck for color on commercialization cadence and margin levers — useful for modeling timing of expected benefits from new assays. Earnings Call Transcript
• Negative Sentiment: Despite the beat, shares fell (reports of a >5% drop) as traders reacted to mixed takeaways — a beat with in‑line guidance and continued negative margins often triggers profit‑taking. MSN: Shares Slide
• Negative Sentiment: Profitability concerns remain: NeoGenomics reported a negative net margin (~16%) and negative ROE (~3.4%); analysts still expect negative full‑year EPS, keeping investor focus on when margins will turn. BusinessWire: 2025 Results

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.